UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.657

Sortiert nach

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

Circulation (New York, N.Y.), 2000-07, Vol.102 (2), p.149-156

2000

Volltextzugriff (PDF)

Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure

European heart journal, 2008-01, Vol.29 (1), p.12-20

2008

Volltextzugriff (PDF)

Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency : Implications for assay methodology and comparison of different antagonists

Circulation (New York, N.Y.), 1998-10, Vol.98 (16), p.1616-1621

1998

Volltextzugriff (PDF)

Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes

Thrombosis and haemostasis, 2001-03, Vol.85 (3), p.401

2001

Volltextzugriff (PDF)

Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT

European heart journal, 2000-03, Vol.21 (5), p.371-381

2000

Volltextzugriff (PDF)

Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience

Heart (British Cardiac Society), 2002-10, Vol.88 (4), p.357-362

2002

Volltextzugriff (PDF)

Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes

Circulation (New York, N.Y.), 2000-02, Vol.101 (7), p.751-757

2000

Volltextzugriff (PDF)

Relevance of clinical trial results in myocardial infarction to medical practice: comparison of four year outcome in participants of a thrombolytic trial, patients receiving routine thrombolysis, and those deemed ineligible for thrombolysis

Heart (British Cardiac Society), 1999-06, Vol.81 (6), p.598-602

1999

Volltextzugriff (PDF)

Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II

European heart journal, 2001-09, Vol.22 (18), p.1702-1715

2001

Volltextzugriff (PDF)

Cardiac rupture associated with thrombolytic therapy: Impact of time to treatment in the late assessment of thrombolytic efficacy (LATE) study

Journal of the American College of Cardiology, 1995-04, Vol.25 (5), p.1063-1068

1995

Volltextzugriff (PDF)

TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION: Anglo-Scandinavian Study of Early Thrombolysis (ASSET)

The Lancet (British edition), 1988-09, Vol.332 (8610), p.525-530

1988

Volltextzugriff (PDF)

Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial

The Lancet (British edition), 2001-12, Vol.358 (9296), p.1855-1863

White, H

2001

Volltextzugriff (PDF)

Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study

The Lancet (British edition), 2001-04, Vol.357 (9262), p.1063-1068

2001

Volltextzugriff (PDF)

High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive

Diabetes, obesity & metabolism, 2011-08, Vol.13 (8), p.759-764

2011

Volltextzugriff (PDF)

Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study

The Lancet (British edition), 1990-05, Vol.335 (8699), p.1175-1178

1990

Volltextzugriff (PDF)

Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation A phase II study

European heart journal, 2000-12, Vol.21 (24), p.2042-2055

2000

Volltextzugriff (PDF)

Acute myocardial infarction in the young—the role of smoking

European heart journal, 1995-03, Vol.16 (3), p.313-316

1995

Volltextzugriff (PDF)

A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies

Thrombosis and haemostasis, 1999-10, Vol.82 (4), p.1307

1999

Volltextzugriff (PDF)

Clinical Trials in Thrombolytic Therapy: What Do They Tell Us? INJECT 6-Month Outcomes Data

The American journal of cardiology, 1996-12, Vol.78 (12), p.20-23

Wilcox, Robert G

1996

Volltextzugriff (PDF)

New atrial fibrillation after acute myocardial infarction independently predicts death: The GUSTO-III experience

The American heart journal, 2000-12, Vol.140 (6), p.878-885

2000

Volltextzugriff (PDF)

Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction

Journal of the American College of Cardiology, 1997-07, Vol.30 (1), p.171-179

1997

Volltextzugriff (PDF)

ST-segment elevation resolution — a surrogate for infarct vessel patency or myocardial perfusion, but a call for rescue?

European heart journal, 2001-05, Vol.22 (9), p.722-724

Wilcox, R G

2001

Volltextzugriff (PDF)

Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction

European heart journal, 2001-11, Vol.22 (22), p.2104-2115

2001

Volltextzugriff (PDF)

Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood

Thrombosis and haemostasis, 1995-11, Vol.74 (5), p.1310

1995

Volltextzugriff (PDF)

Refined structure in solution of the sea anemone neurotoxin ShI

The Journal of biological chemistry, 1993-11, Vol.268 (33), p.24707-24719

1993

Volltextzugriff (PDF)

1 – 25 von 1.657

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.467)
Mit Volltextzugriff
(1.411)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.073)
Life Sciences & Biomedicine
(873)
Humans
(627)
Biological And Medical Sciences
(443)
Male
(409)
Female
(394)
Medical Sciences
(315)
Animals
(260)
Middle Aged
(243)
Adult
(212)
Aged
(175)
Physical Sciences
(158)
Fundamental And Applied Biological Sciences. Psychology
(143)
Cardiovascular System & Cardiology
(118)
Technology
(108)
Cardiac & Cardiovascular Systems
(103)
General & Internal Medicine
(101)
Pharmacology. Drug Treatments
(86)
Medicine, General & Internal
(84)
Physics
(75)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure

Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency : Implications for assay methodology and comparison of different antagonists

Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes

Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT

Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience

Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes

Relevance of clinical trial results in myocardial infarction to medical practice: comparison of four year outcome in participants of a thrombolytic trial, patients receiving routine thrombolysis, and those deemed ineligible for thrombolysis

Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II

Cardiac rupture associated with thrombolytic therapy: Impact of time to treatment in the late assessment of thrombolytic efficacy (LATE) study

TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION: Anglo-Scandinavian Study of Early Thrombolysis (ASSET)

Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial

Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study

High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive

Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study

Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation A phase II study

Acute myocardial infarction in the young—the role of smoking

A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies

Clinical Trials in Thrombolytic Therapy: What Do They Tell Us? INJECT 6-Month Outcomes Data

New atrial fibrillation after acute myocardial infarction independently predicts death: The GUSTO-III experience

Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction

ST-segment elevation resolution — a surrogate for infarct vessel patency or myocardial perfusion, but a call for rescue?

Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction

Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood

Refined structure in solution of the sea anemone neurotoxin ShI

Suchergebnisse filtern